Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22543794 | 0.76 | CDK1 (0.37) | ARCDK1KDRALDH1A1POLB | |
| SCHEMBL2739656 | 0.76 | HRH4 (0.41) | ARCDK1KDRALDH1A1L3MBTL1 | |
| SCHEMBL12775196 | 0.76 | KDM5A (0.36) | ARALDH1A1L3MBTL1POLBKDM4E | |
| SCHEMBL810127 | 0.74 | L3MBTL1 (0.33) | ARALDH1A1L3MBTL1POLBKDM4E | |
| SCHEMBL5857653 | 0.74 | TRPV4 (0.33) | ARALDH1A1L3MBTL1POLBMAPT | |
| SCHEMBL810776 | 0.74 | KDM4E (0.41) | ALDH1A1KDM4EMAPT | |
| SCHEMBL4760466 | 0.74 | ALDH1A1 (0.45) | ARALDH1A1L3MBTL1POLBKDM4E | |
| SCHEMBL531211 | 0.74 | MAPK1 (0.33) | ARALDH1A1L3MBTL1POLBMAPT | |
| SCHEMBL30283054 | 0.74 | ALDH1A1 (0.45) | ARALDH1A1L3MBTL1POLBKDM4E | |
| SCHEMBL15429601 | 0.74 | NOS3 (0.37) | ARCDK1KDRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | AR 3772/4885CDK1 14/4885KDR 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.